As of November 17, 2022, Seres Therapeutics Inc had a $853.5 million market capitalization, putting it in the 62nd percentile of companies in the Biotechnology & Medical Research industry. Seres ...
The global microbiome therapeutics market is anticipated to witness an impressive growth during the forecast period, 2023-2027. This can be ascribed to the growing prevalence of diseases like ...
At this time, I would like to welcome everyone to the Third Quarter 2022 Seres Therapeutics, Inc. Earnings Conference Call. [Operator Instructions] Thank you. I will now turn the call over to Dr ...
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported third quarter 2022 financial results and provided business updates. “Our recent progress, highlighted ...
November 02, 2022--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported third quarter 2022 financial results and provided business ...
Seres continues to execute pre-commercialization activities in collaboration with Aimmune Therapeutics, including appropriate market education and data dissemination to the medical community.
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do ...